Hennion & Walsh Asset Management Inc. Sells 6,380 Shares of Hologic, Inc. (NASDAQ:HOLX)

Hennion & Walsh Asset Management Inc. decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 38.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 10,417 shares of the medical equipment provider's stock after selling 6,380 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Hologic were worth $643,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. LaFleur & Godfrey LLC grew its position in shares of Hologic by 2.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after purchasing an additional 3,655 shares during the last quarter. Yousif Capital Management LLC boosted its stake in Hologic by 0.6% in the 4th quarter. Yousif Capital Management LLC now owns 46,219 shares of the medical equipment provider's stock valued at $3,332,000 after purchasing an additional 294 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Hologic by 27.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,939 shares of the medical equipment provider's stock valued at $1,954,000 after buying an additional 5,825 shares in the last quarter. Choreo LLC increased its position in Hologic by 14.2% during the 4th quarter. Choreo LLC now owns 6,646 shares of the medical equipment provider's stock worth $480,000 after buying an additional 825 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Hologic by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 544,170 shares of the medical equipment provider's stock worth $39,229,000 after buying an additional 15,820 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Hologic stock traded down $0.71 during midday trading on Wednesday, reaching $64.43. The company's stock had a trading volume of 1,684,424 shares, compared to its average volume of 2,300,771. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.36 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The business has a 50-day moving average price of $58.42 and a 200-day moving average price of $65.16.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $1.03 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.88% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HOLX shares. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Royal Bank of Canada decreased their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Evercore ISI dropped their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Raymond James reissued an "outperform" rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.